Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1169
Article Code: 1169b
Date: November 10, 2003
Volume: 45
Pages: 90-92
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1169
Article Code: 1169b
Date: November 10, 2003
Volume: 45
Pages: 90-92
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
